With focus on fibrosis

About Anamar
About Anamar


AnaMar AB develops novel, selective drugs for the treatment of a broad range of fibrotic disorders. These disorders affect millions of patients who suffer from organ dysfunction, and who have limited, if any, treatment options. These chronic disorders arise when certain cells become over-activated as a result of tissue injury.

AnaMar is developing molecules that selectively block a specific serotonin receptor, the 5-HT2B receptor, which plays an important role in fibrotic disorders by modifying/inhibiting cell activation. AnaMar’s lead project is in the lead-optimization phase and is focused on treatment of life-threatening, orphan diseases e.g. idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc).

AnaMar AB is a privately held company located at Medicon Village in Lund, Sweden.